Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
The survival of subjects with unresectable hepatocellular carcinoma (HCC) receiving transarterial chemoembolization is improved with addition of axitinib.
Hepatocellular Carcinoma
DRUG: Axitinib
Two-year survival rate, 4 years
Overall confirmed objective response rate (ORR) as determined according to modified RECIST., 4 years|Disease Control Rate (DCR), 4 Years|Duration of Response (DR), 4 years|Time to Progression (TTP), 4 years|Progression-Free Survival (PFS), 4 years|Overall survival (OS), 4 years|Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, 4 years|Quality of Life, 4 years|Tissue and Serum Biomarkers, 4 years
The survival of subjects with unresectable hepatocellular carcinoma (HCC) receiving transarterial chemoembolization is improved with addition of axitinib.